drugset / Trial / NCT00579878

Triple III Comparison of Leflunomide Alone Versus Two DMARD Combinations in the Treatment of Rheumatoid Arthritis

NCT00579878

Phase 3 Completed 69 enrolled University of Nebraska
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study has been designed as a 48-week, double-blind, randomized, controlled study comparing the use of leflunomide alone to combinations of leflunomide-sulfasalazine-HCQ, and methotrexate-sulfasalazine-HCQ.

Timeline

Start
2001-03-27
Primary completion
2010-03-11
Completion
2010-03-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Hydroxychloroquine Small molecule 400 mg
Comparator Leflunomide Small molecule 20 mg
Comparator Methotrexate Small molecule 20 mg
Comparator Sulfasalazine Small molecule 2000 mg

Indications